Transcranial static magnetic field stimulation can modify disease progression in Amyotrophic Lateral Sclerosis by Di Lazzaro, Vincenzo et al.
lable at ScienceDirect
Brain Stimulation 14 (2021) 51e54Contents lists avaiBrain Stimulation
journal homepage: http: / /www.journals .e lsevier .com/brain-st imulat ionTranscranial static magnetic field stimulation can modify disease






1935-861X/© 2020 The Authors. Published by ElsevierIn thi
tSMS inDear Editor,
Glutamate-mediated excitotoxicity is thought to play a pivotal
role in the pathogenesis of amyotrophic lateral sclerosis (ALS) [1].
Current pharmacological treatments target glutamatergic neuro-
transmission, with limited efficacy. Cerebral cortex excitatory
transmission can be targeted and modulated using non-invasive
brain stimulation techniques such as repetitive transcranial mag-
netic stimulation (rTMS), with the purpose of antagonizing motor
cortical hyper-excitability.
RTMS was tested in several small studies [2], demonstrating a
slight reduction of ALS progression related to duration and fre-
quency of treatment. The main limitations of rTMS are that its
after-effects are short-lived and that it can be performed only in
specialized centers. Other techniques, such as transcranial direct
current stimulation (tDCS), can be performed more easily, even un-
der remote supervision at patient’s home [3]. Inhibitory tDCS was
evaluated in ALS in two studies but the results are controversial
[4,5]. Motor cortex stimulation can also be performed invasively us-
ing implanted electrodes, and it can be delivered chronically with
obvious advantages. Epidural motor cortex stimulation (eMCS) pro-
duces physiologic effects that are comparable to those of rTMS [6]
and it has been evaluated in a single patient with rapidly progres-
sive ALS: he was implanted in 2006 and he is surprisingly still alive
after 14 years [7]. The benefit of eMCS was recently confirmed in a
murine model of ALS [8]. Thus, the dose-effect observed in non-
invasive studies and the pronounced effect of eMCS both in humans
and in animals, suggest that chronic motor cortex stimulation
might be effective in slowing ALS progression.
Recently, a new technique of non-invasive transcranial static
magnetic field stimulation (tSMS) [9] has been shown to suppress
motor cortex excitability of healthy subjects for 10e30 min [9,10].
Since tSMS does not require any electronic equipment, it is easily
performed and suitable for daily chronic administration at patients’
site.Inc. This is an open access article us open-label pilot study we evaluated the effects of chronic
two patients with rapidly progressive non-familial ALS,
both taking Riluzole, treated under “compassionate use” authoriza-
tion (Supplementary material). Moreover, in order to test more
directly whether tSMS may reverse cortical hyper-excitability in
ALS patients, we assessed the effects of a single tSMS session on
cortical excitability.
Disease severity was evaluated using the revised ALS Functional
Rating Scale (ALSFRS-R). The first patient, a 50-year-old male,
started to present right upper limb weakness in November 2015.
At the first evaluation, in July 2017, 13 months before the beginning
of stimulation, the ALSFRS-R score was 30. In the following months
the patient developed progressive bulbar involvement with
dysphagia and in July 2018, because of a respiratory crisis, tracheos-
tomy was performed and ventilation during sleep was started.
Because of severe dysphagia, percutaneous endoscopic gastro-
stomy was also performed at the same time, to ensure nutritional
support. TSMS was started in August 2018: at that time, he was tra-
cheotomized and required tube feeding, ALSFRS-R score was 13
(Fig. 1A). The second patient, a 54-year-old female, started to pre-
sent lower limbweakness in December 2017. At the first evaluation,
in October 2018, the ALSFRS-R score was 30. TSMS was started in
May 2019: at that time ALSFRS-R score was 17 (Fig. 1A).
In both patients, tSMS was performed daily without any inter-
ruption and it is still ongoing. Stimulation was self-administered
at patients’ home, for 3 times every day at least 4 hours apart; in
each session tSMS was applied sequentially for 20 minutes over
each motor cortex. TSMS was delivered using a cylindrical Nickel-
plated NdFeB magnet of 45 mm diameter with a nominal field
strength of ~69 Kg (MAG45r, Neurek, Toledo, Spain), held in place
by an ergonomic helmet specifically designed to target the motor
cortex (MAGmv1.0, Neurek) (Supplementary material).
Disease monthly progression rate (MPR) was measured as the
variation of the ALSFRS-R score over the period of observation. In
each patient, we compared MPR before and during stimulation.
We also compared disease progressionwith that of control patients’
groups with comparable functional impairment, obtained from the
Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Data-
base (Fig. 1B; Supplementary material). Patients were evaluated
at least 6months before treatment and at multiple time points after
tSMS beginning, up to 18 months in Patient 1 and up to 9 months in
Patient 2.
Both patients and caregivers did not report any difficulty in per-
forming chronic tSMS. Both patients needed a headrest to sustain
the helmet during the procedure. No side effects were reported.
Acute effects of tSMS on primary motor cortex (M1) excitability
were characterized by a reduction of about 20% of the mean motornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A) Disease progression as evaluated with the revised ALS Functional Rating Scale (ALSFRS-R). TSMS started at month 0. The dashed line indicates the expected clinical
status based on the individual progression before tSMS, assuming a linear worsening of the functional performance. The dotted line indicates disease progression in the control
population extracted from the PRO-ACT database (Panel B). The actual clinical status is indicated by the continuous line. mpr: monthly progression rate (points/months). B) Left
panel: survival probability functions (thick lines) calculated in control samples extracted from the PRO-ACT database, including ALS patients having an initial ALSFRS-R score of
12e14 (control for Patient 1) and of 16e18 (control for Patient 2) and observed for 2 years. Upper and lower bounds of survival curves (thin lines) delimit the 95% confidence
interval. Survival rate at each time point is calculated as the ratio between the number of patients alive and the number of patients at risk, i.e. excluding censored patients. Grey bars
indicate the proportion of the population that is still under observation at each time point (i.e. initial population minus censored patients). The estimated survival probability at the
last time of observation after starting tSMS is 0.23 for Patient 1 and 0.43 for Patient 2. Right panel: monthly progression rate of Patients 1 and 2 before and during tSMS, in
comparison with that of control samples extracted from the PRO-ACT database with initial ALSFRS-R scores of 29e31, 12e14 and 16e18 (boxplots). Control samples include only
patients who were still alive at the end of observation, with a minimum follow-up of 3 months. Boxplots represent the lower quartile, median and upper quartile of the sample
distribution; whiskers are set with a maximum length of 1.5 times the interquartile range; þ symbols indicate outliers. Patient 1 scores in the upper 25th percentile of its reference
group before starting tSMS (i.e. faster progression) and in the lower 20th percentile during tSMS (i.e. slower progression). Patient 2 scores in the upper 13th percentile of its
reference group before starting tSMS and in the lower 40th percentile during tSMS.
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sion of right M1 tSMS in Patient 1 (126 ± 21 (SD) mV at baseline vs
102 ± 15 mV (SD) after tSMS), comparable with the reduction52observed in normal subjects [9]. In Patient 2, due to pronounced
involvement of upper and lower motor neuron, no MEPs could be
recorded after stimulation of both motor cortices.
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Fig. 1.
In Patient 1, survival probability at last observation (18 months)
is estimated at 0.23, based on the survival function of the control
population (Fig. 1B). After the beginning of stimulation, the overall
functional status remained stable (MPR reduced to 0.06, in the
lower 20th percentile of control population): it was mainly charac-
terized by improvement of swallowing function (not requiring sup-
plemental tube feeding or dietary consistency changes) and loss of
functional lower limb movement; the patient continued to require
ventilatory support during night only. The overall a priori probabil-
ity, at the moment of starting tSMS, of surviving and of being in the
observed clinical conditions at the last observation can thus be esti-
mated at ~0.05, i.e. 0.23 (survival probability)  0.20 (probability of
MPR  0.06) (Fig. 1B).
In Patient 2, survival probability at last observation (9 months) is
estimated at 0.43 (Fig. 1B). After the beginning of stimulation, MPR
was reduced to 0.56 (lower 40th percentile of control population),
due to slight deterioration of bulbar function and loss of residual
lower limb movement. The overall a priori probability of surviving
and of being in the observed clinical conditions at the last observa-
tion can be estimated at ~0.17, i.e. 0.43 (survival probability)  0.40
(probability of MPR  0.56) (Fig. 1B).
In conclusion, we observed a dramatic and prolonged reduction
in disease progression in two patients with rapidly progressive ALS
treated chronically with tSMS. Patients reported no side effects and
at-home self-administered stimulation was considered feasible
both by patients and their caregivers.
Considering that our patients had a rapidly progressive form of
ALS, the fact that the first patient is still alive and stable, requiring
ventilation only during sleep, and has also recovered speech and
swallowing functions and that the second patient is also stable
and still not tracheotomized suggests a pronounced change in dis-
ease course. Comparison with a large control population from the
PRO-ACT database indicates that both patients had a low survival
probability and a slower disease progression during tSMS than their
respective control groups. Of note, we might have even overesti-
mated survival in our 2-year period of analysis since many patients
in the PRO-ACT database had a shorter follow-up. The study of mo-
tor cortex excitability before and after a single session of tSMS in
Patient 1 shows for the first time that it is possible to reduce cortical
excitability in ALS with an effect that is comparable to that
observed in normal subjects.
Our study has obvious limitations, because only two patients
were treated and because we used a historical control group.
Nevertheless, present results show that long-term self-adminis-
tered tSMS is safe and feasible at home and suggest that it has
therapeutic potential in ALS. Based on these preliminary observa-
tions we have now started a placebo-controlled trial evaluating
tSMS as a disease-modifying treatment in ALS (Clinicaltrials.gov:
NCT04393467).
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